Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment
Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment
复制标题
DOI：
10.1002/hep.21261
复制
发表时间：
2006-08-01
期刊：
影响因子：
13.5
通讯作者：
Min, Albert D.
中科院分区：
文献类型：
--
作者：
Gopal, Kavitha;Johnson, Timothy C.;Min, Albert D.
低密度脂蛋白受体（LDLR）已被提议作为丙型肝炎病毒（HCV）的候选受体。体外研究表明，低密度脂蛋白（LDL）可竞争性抑制HCV与LDLR的结合。如果在体内发生类似的抑制，则升高的血清β-脂蛋白浓度可能通过竞争性抑制HCV病毒受体结合而降低HCV感染肝细胞的效率。我们研究了基线血脂值在影响HCV治疗结果中的作用。我们对1998年至2004年在我们的肝脏和胃肠病诊所接受基于干扰素方案治疗的患者进行了回顾性图表审查。在入组研究的99例患者中，49例（49.5%）为HCV基因型1（LDL 100.2 +/- 30.2 mg/dL [平均值+/- SD]），50例（50.5%）为基因型2或3（LDL 110.1 +/- 40 mg/dL）感染。分别在99、88和77例患者中记录了早期病毒应答（EVR）、治疗结束应答（ETR）和持续病毒应答（SVR）。在EVR、ETR和SVR阳性的患者中，发现治疗前的LDL和胆固醇水平较高。这种差异与年龄无关。控制基因型和年龄的多变量分析显示，治疗前胆固醇和LDL水平越高，对治疗反应的几率越大。总之，治疗前血清LDL和胆固醇水平较高可能是慢性丙型肝炎感染者治疗结果的重要预后指标，特别是基因型1和2。
The low-density lipoprotein receptor (LDLR) has been proposed as a candidate receptor for the hepatitis C virus (HCV). Competitive inhibition of HCV binding to the LDLR by low-density lipoprotein (LDL) has been shown in vitro. If similar inhibition occurs in vivo, an elevated serum concentration of beta-lipoproteins may reduce the efficiency of infecting hepatocytes with HCV by competitively inhibiting HCV viral receptor binding. We investigated the role of baseline lipid values in influencing the outcome of HCV treatment. We conducted a retrospective chart review of patients treated with an interferon-based regimen at our liver and gastroenterology clinics between 1998 and 2004. Of 99 patients enrolled in the study, 49 (49.5%) had HCV genotype 1 (LDL 100.2 +/- 30.2 mg/dL [mean +/- SD]), and 50 patients (50.5%) had genotype 2 or 3 (LDL 110.1 +/- 40 mg/dL) infection. Early viral response (EVR), end-of-treatment response (ETR), and sustained viral response (SVR) were documented in 99, 88, and 77 patients, respectively. LDL and cholesterol levels prior to treatment were found to be higher in patients with positive EVR, ETR, and SVR. This difference remained significant independent of age. Multivariate analysis controlling for genotype and age showed that the higher the cholesterol and LDL levels prior to treatment, the greater the odds of responding to treatment. In conclusion, having higher serum LDL and cholesterol levels before treatment may be significant prognostic indicators for treatment outcome of those with chronic hepatitis C infection, particularly in genotypes 1 and 2.